Aravive announces publication of AVB-500 nonclinical study in in Cancer Research
Aravive announced publication of data from a nonclinical study of AVB-500, the company’s lead product candidate, which demonstrated reduction in tumor size and blood vessel density in animal models of clear cell renal cell carcinoma. The study was published in the journal Cancer Research. October 18, 2019